Noxafil (Posaconazole)

Brand Name

Noxafil

Generic Name

Posaconazole

View Brand Information

FDA approval date: September 15, 2006

Classification: Azole Antifungal

Form: Injection, Tablet, Powder, Suspension, Solution

What is Noxafil (Posaconazole)?

Posaconazole delayed-release tablets is an azole antifungal indicated as follows: Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows.

Approved To Treat

Aspergillosis

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

Who is this study for: Patients with myeloid malignancies

Enrollment Status: Recruiting

Publish Date: April 14, 2026

Intervention Type: Drug

Study Drugs: BGB-11417, Azacitidine, Posaconazole

Study Phase: Phase 1/Phase 2

Summary: The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia and Other Selected Hematologic Malignancies, With and Without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation (Horizen-1)

Who is this study for: Adults with acute leukemia with and without mixed lineage leukemia-rearrangement or nucleophosmin 1 mutation

Enrollment Status: Recruiting

Publish Date: March 24, 2026

Intervention Type: Drug

Study Drug: DSP-5336

Study Phase: Phase 1/Phase 2

Summary: A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

Enrollment Status: Recruiting

Publish Date: March 18, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.

View All Clinical Trials

Related Latest Advances

Establishment of epidemiological cutoff values for clinically relevant Sporothrix species using CLSI-broth microdilution.

Journal: Antimicrobial agents and chemotherapy

Published: April 06, 2026

Analysis of interactions between posaconazole/voriconazole and venetoclax.

Journal: Antimicrobial agents and chemotherapy

Published: March 31, 2026

Successful Outcome of Rhino-Orbital-Cerebral Mucormycosis With Extensive Intracranial Disease in a Patient With Poorly Controlled Diabetes.

Journal: The Permanente journal

Published: March 23, 2026

View All Latest Advances